Aberrant Super-Enhancer Landscape in Enzalutamide-Resistant Prostate Cancer Cells-Reference-Cited by-同舟云学术

Aberrant Super-Enhancer Landscape in Enzalutamide-Resistant Prostate Cancer Cells

Published:2024-06-01 Issue:6 Volume:28 Page:243-256
ISSN:1945-0265
Container-title:Genetic Testing and Molecular Biomarkers
language:en
Short-container-title:Genetic Testing and Molecular Biomarkers

Author:

Cai Chao¹^ORCID,Liu Qinwei¹,Shan Haoran¹,Zhong Chuanfan²,Chen Guidong³,Cai Zhouda⁴,Zheng Yu⁵,Lu Jianming⁴^ORCID,Tang Jiaojiao⁶,Lin Zhuoyuan⁵^ORCID

Affiliation:

1. Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Key Laboratory of Urology, Guangzhou Institute of Urology, Guangzhou, China.

2. Zhujiang Hospital, Southern Medical University, Guangzhou, China.

3. Department of Pathology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

4. Department of Andrology, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, China.

5. Department of Urology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.

6. Department of Cardiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

Publisher

Mary Ann Liebert Inc

Link

https://www.liebertpub.com/doi/pdf/10.1089/gtmb.2023.0280

Reference64 articles.

1. Genomic correlates of clinical outcome in advanced prostate cancer

2. Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor

3. Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer

4. IKBKE activity enhances AR levels in advanced prostate cancer via modulation of the Hippo pathway

5. Integrated high-throughput analysis identifies super enhancers associated with chemoresistance in SCLC